NasdaqGS:VRTXBiotechs
Assessing Vertex Pharmaceuticals (VRTX) Valuation After Autoimmune Pipeline Expansion With WuXi Biologics
Vertex Pharmaceuticals (VRTX) just expanded its autoimmune pipeline through a license and research agreement with WuXi Biologics for a trispecific T cell engager, and the stock now sits squarely on many biotech investors’ radars.
See our latest analysis for Vertex Pharmaceuticals.
The WuXi Biologics agreement comes as Vertex shares trade at US$458.81. Recent weakness is reflected in a 1-day share price return of a 2.49% decline and a 7-day share price return of a 3.55% decline, while a 90-day...